Cargando…

Signet ring colorectal carcinoma: Do we need to improve the treatment algorithm?

AIM: To elaborate about this peculiar variant from a tertiary cancer center from India. METHODS: It’s a retrospective study (2011-2014) of all patients diagnosed with signet ring colo-rectal cancer (SRCC). Various clinico-pathological variables were studied. RESULTS: One hundred and seventy consecut...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamhankar, Anup Sunil, Ingle, Parag, Engineer, Reena, Bal, Munita, Ostwal, Vikas, Saklani, Avanish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156848/
https://www.ncbi.nlm.nih.gov/pubmed/28035252
http://dx.doi.org/10.4251/wjgo.v8.i12.819
Descripción
Sumario:AIM: To elaborate about this peculiar variant from a tertiary cancer center from India. METHODS: It’s a retrospective study (2011-2014) of all patients diagnosed with signet ring colo-rectal cancer (SRCC). Various clinico-pathological variables were studied. RESULTS: One hundred and seventy consecutive patients with SRCC were diagnosed (11.4% of all colorectal cancers). Median Age of the cohort was 41 years. Most common location was recto-sigmoid area (54.7%). Majority patients presented in stage III and IV (91.2%). Most of the stage IV patients had isolated peritoneal metastases (86.5%). Colonic tumors had higher incidence of peritoneal metastases (91.8% vs 83.3%) as well as isolated peritoneal recurrences (37.5% vs 16.7%) than rectal primaries. Thirty-seven point five percent of patients recurred after curative surgery. Amongst them 63.63% patients had isolated peritoneal recurrences. Circumferential resection margin (CRM) was involved in 17.9% patients. Median relapse free survival (RFS) and overall survival (OS) of the cohort were 14.9 and 18.13 mo respectively. CRM involvement, colonic primary were associated with poorer RFS and OS. CONCLUSION: SRCC has predilection for peritoneal dissemination. More aggressive and/or extended chemotherapy schedules as well as prophylactic hyperthermic intra-peritoneal chemotherapy at the time of primary surgery may be attempted in these patients.